OSLO, Norway, Oct. 19, 2020 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage immuno-oncology company
developing oncolytic viruses to target hard-to-treat solid tumors,
today announces that an abstract on the mesothelioma trial has been
accepted and will be presented at the Society for Immunotherapy of
Cancer (SITC) 35th Anniversary Annual Meeting, 9 -14 November 2020.
The abstract presents the 12-month analysis of biomarkers and
clinical outcome from the phase I/II trial in malignant pleural
mesothelioma where ONCOS-102 is added to standard of care
chemotherapy (pemetrexed / cisplatin). This analysis supports the
data presented in June.
Abstract
title
|
A randomised
open-label phase I/II study adding ONCOS-102 to
pemetrexed/cisplatin in patients with unresectable malignant
pleural mesothelioma - 12-month analysis of biomarkers and clinical
outcomes
|
Abstract
number
|
361
|
Poster
session
|
ePoster available
throughout the conference
|
About SITC Annual Meeting 2020
The Society for Immunotherapy of Cancer's (SITC) 35th
Anniversary Annual Meeting & Pre-Conference Programs (SITC
2020) will be reimagined as a fully VIRTUAL experience this year to
ensure the health and safety of program attendees and their
patients.
SITC 2020 provides a multidisciplinary educational and
interactive environment focused on improving cancer patient
outcomes by incorporating strategies based on basic and applied
cancer immunotherapy.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas
Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-announces-accepted-abstract-at-sitc,c3217908